Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Open to people ages 18-75

• Histologically confirmed renal cell carcinoma with a predominant clear cell component.
• Must have received a checkpoint inhibitor and a VEGF inhibitor in the advanced and/or metastatic setting.
• At least one measurable lesion as defined by RECIST version 1.1
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
• Absence of donor (product)-specific anti-HLA antibodies (DSA).
• Adequate hematological, renal, liver, pulmonary, and cardiac functions.

• Central nervous system (CNS) metastatic disease (unless controlled and stable for at least 4 weeks), leptomeningeal disease, or cord compression.
• Clinically significant CNS dysfunction.
• Any other active malignancy within 3 years prior to enrollment.
• Prior treatment with anti-CD70 therapies.
• Current thyroid disorder (including hyperthyroidism) with the exception of hypothyroidism controlled on stable dose of hormone replacement therapy.
• Prior treatment with anti-CD52 monoclonal antibody in the past 12 months.
• Patients unwilling to participate in the extended safety monitoring period.